Last reviewed · How we verify

NCT03788694

Intranasal Ketamine for Suicidal Ideation in Veterans

Withdrawn EARLY_PHASE1 Last updated 7 August 2023
What this trial tests

EARLY_PHASE1 trial testing Ketamine in Suicidal Ideation. Withdrawn.

Timeline
1 January 2020
Primary endpoint
31 January 2020
30 April 2020

Quick facts

Lead sponsorBronx Veterans Medical Research Foundation, Inc
PhaseEARLY_PHASE1
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Start date1 January 2020
Primary completion31 January 2020
Estimated completion30 April 2020
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Bronx Veterans Medical Research Foundation, Inc

Who can join

Adults 21 to 70, any sex, with Suicidal Ideation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of the current study is to investigate the safety, efficacy, and feasibility of multiple doses of intranasal (IN) ketamine for suicidal ideation Veterans.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Open Clinical Trials for Veterans With Suicidal Ideation.
    · 2019 · PMID 31772493

Verify or expand the search:

Other trials of Ketamine

Trials testing the same drug.

Other recruiting trials for Suicidal Ideation

Currently open trials in the same condition.

Other Bronx Veterans Medical Research Foundation, Inc trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03788694.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing